EPISODE · Jun 3, 2025 · 11 MIN
ASCO 2025: PharmaMar presented data showing that the combo of Zepzelca and Tecentriq significantly improved survival as first-line maintenance therapy for extensive-stage small cell lung cancer
from BiotechTV - News · host BiotechTV
Global Product Lead José Antonio López-Vilariño describes the data and VP of Strategic Development Pascal Besman puts the result in context of this cancer type and stage that historically has had a very poor prognosis.
Embed this episode
NOW PLAYING
ASCO 2025: PharmaMar presented data showing that the combo of Zepzelca and Tecentriq significantly improved survival as first-line maintenance therapy for extensive-stage small cell lung cancer
0:00
11:40
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 11 minutes long.
When was this BiotechTV - News episode published?
This episode was published on June 3, 2025.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!